Published in J Virol on October 01, 1995
Hepatitis B virus biology. Microbiol Mol Biol Rev (2000) 7.58
CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol (2003) 4.42
Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med (2000) 3.93
IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J Clin Invest (2011) 3.59
Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A (2004) 3.16
Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest (2010) 3.10
Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol (2005) 2.94
Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci U S A (2002) 2.71
Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc Natl Acad Sci U S A (1996) 2.68
Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol (2000) 2.65
Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol (1997) 2.50
Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol (2000) 2.49
Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) (2010) 2.48
Hepatitis B virus replication. World J Gastroenterol (2007) 2.30
Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol (2000) 2.23
Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol (2005) 2.13
Viral and cellular determinants involved in hepadnaviral entry. World J Gastroenterol (2007) 2.07
Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice. J Virol (1998) 2.06
Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J Virol (2002) 2.05
An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci U S A (2006) 1.99
Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci U S A (2004) 1.96
Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism. Proc Natl Acad Sci U S A (2001) 1.88
Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol (1997) 1.87
Enhancement of hepatitis B virus replication by its X protein in transgenic mice. J Virol (2002) 1.78
Posttranscriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes. Proc Natl Acad Sci U S A (1995) 1.76
Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A (2009) 1.76
The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol (2009) 1.71
Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Co-transporting Polypeptide. PLoS Pathog (2015) 1.66
Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice. J Virol (2002) 1.66
MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J Clin Invest (2004) 1.65
CD40 activation rescues antiviral CD8⁺ T cells from PD-1-mediated exhaustion. PLoS Pathog (2013) 1.65
Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus. J Virol (2003) 1.65
Members of the nuclear receptor superfamily regulate transcription from the hepatitis B virus nucleocapsid promoter. J Virol (1997) 1.64
Immune tolerance split between hepatitis B virus precore and core proteins. J Virol (2005) 1.63
Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol (2002) 1.61
Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc Natl Acad Sci U S A (2003) 1.58
Inhibition of hepatitis B virus replication by interferon requires proteasome activity. J Virol (2002) 1.58
Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections. J Virol (2002) 1.56
Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB. J Virol (2003) 1.55
Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein. J Virol (2007) 1.51
Gene expression during the priming phase of liver regeneration after partial hepatectomy in mice. Proc Natl Acad Sci U S A (2002) 1.51
Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest (1996) 1.48
Noncytopathic clearance of lymphocytic choriomeningitis virus from the hepatocyte. J Exp Med (1999) 1.47
Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci U S A (2005) 1.47
Blockade of NKG2D on NKT cells prevents hepatitis and the acute immune response to hepatitis B virus. Proc Natl Acad Sci U S A (2007) 1.46
Nuclear covalently closed circular viral genomic DNA in the liver of hepatocyte nuclear factor 1 alpha-null hepatitis B virus transgenic mice. J Virol (2001) 1.43
Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther (2013) 1.42
Hepatitis B virus X protein acts as a tumor promoter in development of diethylnitrosamine-induced preneoplastic lesions. J Virol (2001) 1.42
The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice. J Virol (1996) 1.40
Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes. J Virol (2003) 1.39
A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology (2011) 1.38
A short N-proximal region in the large envelope protein harbors a determinant that contributes to the species specificity of human hepatitis B virus. J Virol (2001) 1.38
Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein. J Virol (2001) 1.36
Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol (2012) 1.36
Nitric oxide inhibits hepatitis B virus replication in the livers of transgenic mice. J Exp Med (2000) 1.35
Transcriptional and posttranscriptional control of hepatitis B virus gene expression. Proc Natl Acad Sci U S A (2003) 1.35
Kupffer cells hasten resolution of liver immunopathology in mouse models of viral hepatitis. PLoS Pathog (2011) 1.34
A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose. J Virol (2010) 1.33
Role of NF-kappaB and myc proteins in apoptosis induced by hepatitis B virus HBx protein. J Virol (2001) 1.32
Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc Natl Acad Sci U S A (2005) 1.30
Transfer of hepatitis B virus genome by adenovirus vectors into cultured cells and mice: crossing the species barrier. J Virol (2001) 1.29
Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (2002) 1.29
Dynamics of hepatitis B virus clearance in chimpanzees. Proc Natl Acad Sci U S A (2005) 1.29
Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol Ther (2013) 1.26
Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges. Cancer Lett (2010) 1.22
HBV pathogenesis in animal models: recent advances on the role of platelets. J Hepatol (2007) 1.20
Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J Virol (2010) 1.18
Carboxypeptidase D is an avian hepatitis B virus receptor. J Virol (1999) 1.18
Hepatitis B virus-cell interactions and pathogenesis. J Cell Physiol (2008) 1.17
Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. J Virol (2013) 1.16
In vivo regulation of hepatitis B virus replication by peroxisome proliferators. J Virol (1999) 1.15
La autoantigen specifically recognizes a predicted stem-loop in hepatitis B virus RNA. J Virol (1999) 1.15
Innate immune responses in hepatitis B virus (HBV) infection. Virol J (2014) 1.11
Host-virus interactions during malaria infection in hepatitis B virus transgenic mice. J Exp Med (2000) 1.10
Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model. Antimicrob Agents Chemother (2004) 1.10
Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities. Virology (2010) 1.10
In vivo expression of a new hepatitis B virus protein encoded by a spliced RNA. J Clin Invest (2000) 1.10
Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother (2001) 1.09
Signal transduction pathways that inhibit hepatitis B virus replication. Proc Natl Acad Sci U S A (2004) 1.08
Expression of hepatitis B virus X protein does not alter the accumulation of spontaneous mutations in transgenic mice. J Virol (2000) 1.08
HBV life cycle is restricted in mouse hepatocytes expressing human NTCP. Cell Mol Immunol (2014) 1.07
Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice. J Virol (1999) 1.06
Immune suppression uncovers endogenous cytopathic effects of the hepatitis B virus. J Virol (2006) 1.05
Hepatitis B virus replication is cell cycle independent during liver regeneration in transgenic mice. J Virol (1997) 1.04
Characterization of nuclear RNases that cleave hepatitis B virus RNA near the La protein binding site. J Virol (2001) 1.04
Rapid pathogenesis induced by a vesicular stomatitis virus matrix protein mutant: viral pathogenesis is linked to induction of tumor necrosis factor alpha. J Virol (2006) 1.04
Detailed characterization of the peptide binding specificity of five common Patr class I MHC molecules. Immunogenetics (2006) 1.03
Host cell-virus cross talk: phosphorylation of a hepatitis B virus envelope protein mediates intracellular signaling. J Virol (1998) 1.03
Adeno-associated virus-mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLA-DR1 molecules. J Virol (2013) 1.03
Comparative study of anti-hepatitis B virus RNA interference by double-stranded adeno-associated virus serotypes 7, 8, and 9. Mol Ther (2008) 1.02
Retracted A NO-releasing derivative of acetaminophen spares the liver by acting at several checkpoints in the Fas pathway. Br J Pharmacol (2002) 1.01
Nucleolar localization of human hepatitis B virus capsid protein. J Virol (2004) 1.00
Developmental regulation of hepatitis B virus biosynthesis by hepatocyte nuclear factor 4alpha. PLoS One (2009) 1.00
Inhibition of hepatitis B virus by oxymatrine in vivo. World J Gastroenterol (2001) 1.00
Efficacy of cationic lipid-DNA complexes (CLDC) on hepatitis B virus in transgenic mice. Antiviral Res (2008) 0.99
The hepatitis B virus X protein transactivates viral core gene expression in vivo. J Virol (1999) 0.98
Role of immunoproteasome catalytic subunits in the immune response to hepatitis B virus. J Virol (2006) 0.98
Recombinant covalently closed circular hepatitis B virus DNA induces prolonged viral persistence in immunocompetent mice. J Virol (2014) 0.98
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate. Cell (1982) 16.71
The molecular biology of the hepatitis B viruses. Annu Rev Biochem (1987) 12.32
Hepatitis B virus immunopathogenesis. Annu Rev Immunol (1995) 8.62
Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell (1986) 6.12
In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus. J Virol (1986) 5.75
A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA. EMBO J (1990) 5.74
HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature (1991) 5.34
Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity. J Virol (1990) 4.57
Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J Virol (1990) 4.26
Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol (1994) 3.34
Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci U S A (1994) 3.34
Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci U S A (1990) 3.25
Expression of hepatitis B virus surface and core antigens: influences of pre-S and precore sequences. J Virol (1987) 3.16
Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice. J Virol (1986) 2.94
A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science (1985) 2.47
Two regions of an avian hepadnavirus RNA pregenome are required in cis for encapsidation. J Virol (1994) 2.38
Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte. J Virol (1994) 2.29
Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice. J Virol (1992) 2.25
Infectious hepatitis B virus from cloned DNA of known nucleotide sequence. Proc Natl Acad Sci U S A (1985) 2.20
Expression and replication of hepatitis B virus genome in transgenic mice. Proc Natl Acad Sci U S A (1989) 2.10
Identification of a promoter element located upstream from the hepatitis B virus X gene. Mol Cell Biol (1987) 2.02
Hepatitis B virus (HBV)-specific cytotoxic T-cell response in humans: production of target cells by stable expression of HBV-encoded proteins in immortalized human B-cell lines. J Virol (1992) 1.94
Chronic type B hepatitis and the "healthy" HBsAg carrier state. Hepatology (1987) 1.94
Analysis of the earliest steps of hepadnavirus replication: genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity. J Virol (1993) 1.89
Hepatitis B virus transactivator X protein is not tumorigenic in transgenic mice. J Virol (1990) 1.80
Hepatitis B virus nucleocapsid particles do not cross the hepatocyte nuclear membrane in transgenic mice. J Virol (1994) 1.77
Interleukin-2 downregulates hepatitis B virus gene expression in transgenic mice by a posttranscriptional mechanism. J Virol (1993) 1.76
Specific expression of hepatitis B surface antigen (HBsAg) in transgenic mice. Science (1985) 1.70
Replication and gene expression of hepatitis B virus in a transgenic mouse that contains the complete viral genome. J Virol (1988) 1.68
Quantification of hepatitis B virus DNA over a wide range from serum for studying viral replicative activity in response to treatment and in recurrent infection. Hepatology (1995) 1.50
Mechanisms of liver-specific gene expression. Curr Opin Genet Dev (1992) 1.30
Tissue preferential expression of the hepatitis B virus (HBV) surface antigen gene in two lines of HBV transgenic mice. J Virol (1988) 1.19
Extrathymic expression of the intracellular hepatitis B core antigen results in T cell tolerance in transgenic mice. J Immunol (1994) 1.04
Detection of hepatitis B virus X gene protein and antibody in type B chronic liver disease. Gastroenterology (1989) 0.98
Nucleotide sequence and exact localization of the neomycin phosphotransferase gene from transposon Tn5. Gene (1982) 13.62
Hepatitis B virus genes and their expression in E. coli. Nature (1979) 10.83
Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med (2001) 8.47
Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity (1996) 8.27
A new sensitive method for qualitative and quantitative assay of neomycin phosphotransferase in crude cell extracts. Gene (1984) 7.36
Nucleotide sequence of bacteriophage fd DNA. Nucleic Acids Res (1978) 7.25
Nucleotide sequence of an RNA polymerase binding site from the DNA of bacteriophage fd. Proc Natl Acad Sci U S A (1975) 7.14
Viral clearance without destruction of infected cells during acute HBV infection. Science (1999) 6.78
Structural analysis of Tn5. Cold Spring Harb Symp Quant Biol (1981) 6.16
Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol (2001) 5.81
A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA. EMBO J (1990) 5.74
Nucleotide sequence of the origin of replication of the Escherichia coli K-12 chromosome. Proc Natl Acad Sci U S A (1979) 5.31
The P gene product of hepatitis B virus is required as a structural component for genomic RNA encapsidation. J Virol (1990) 5.19
Signals regulating hepatitis B surface antigen transcription. Nature (1983) 5.02
Interaction of RNA polymerase with promoters from bacteriophage fd. Eur J Biochem (1977) 4.94
Penicillinase from Bacillus licheniformis: nucleotide sequence of the gene and implications for the biosynthesis of a secretory protein in a Gram-positive bacterium. Nucleic Acids Res (1981) 4.94
Comparative sequence analysis of duck and human hepatitis B virus genomes. J Med Virol (1985) 4.68
Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity. J Virol (1990) 4.57
Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature (1994) 4.42
Replication strategy of human hepatitis B virus. J Virol (1987) 4.42
Transcripts and the putative RNA pregenome of duck hepatitis B virus: implications for reverse transcription. Cell (1985) 4.41
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol (1994) 4.37
Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med (2000) 3.93
Characterization of foot-and-mouth disease virus gene products with antisera against bacterially synthesized fusion proteins. J Virol (1986) 3.89
Nucleotide sequence and genome organization of foot-and-mouth disease virus. Nucleic Acids Res (1984) 3.81
Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome. EMBO J (1992) 3.78
Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology (1999) 3.73
The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med (1996) 3.60
Conversion of bacteriophage fd into an efficient single-stranded DNA vector system. Mol Gen Genet (1980) 3.57
The amino-terminal domain of the hepadnaviral P-gene encodes the terminal protein (genome-linked protein) believed to prime reverse transcription. EMBO J (1988) 3.52
Structure of the orgin of DNA replication of bacteriophage fd. Proc Natl Acad Sci U S A (1978) 3.52
Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest (1995) 3.47
Hepatitis B virus transcription in the infected liver. EMBO J (1984) 3.44
HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol (1993) 3.42
The duck hepatitis B virus pre-C region encodes a signal sequence which is essential for synthesis and secretion of processed core proteins but not for virus formation. J Virol (1987) 3.39
The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med (1995) 3.34
Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci U S A (1994) 3.34
Antibodies against a preselected peptide recognize and neutralize foot and mouth disease virus. EMBO J (1982) 3.32
Synthesis and encapsidation of duck hepatitis B virus reverse transcriptase do not require formation of core-polymerase fusion proteins. Cell (1989) 3.31
Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science (1990) 3.26
Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med (1995) 3.20
Transposition of a DNA sequence determining kanamycin resistance into the single-stranded genome of bacteriophage fd. Mol Gen Genet (1978) 3.19
Expression of hepatitis B virus surface and core antigens: influences of pre-S and precore sequences. J Virol (1987) 3.16
Function of DNA polymerase 3 in DNA replication. Nat New Biol (1971) 3.10
Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med (1993) 3.06
Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest (1997) 2.99
Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice. J Virol (1986) 2.94
Expression and replication of the hepatitis B virus genome under foreign promoter control. Nucleic Acids Res (1987) 2.94
Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med (1991) 2.88
Initiation of deoxyribonucleic acid synthesis. VII. A unique location of the gap in the M13 replicative duplex synthesized in vitro. J Biol Chem (1974) 2.85
HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci U S A (1991) 2.83
Cloned HBV DNA causes hepatitis in chimpanzees. Nature (1982) 2.80
Affinity chromatography of DNA-binding enzymes on single-stranded DNA-agarose columns. Eur J Biochem (1972) 2.76
Structure of the DNA of bacteriophage fd. II. Isolation and characterization of a DNA fraction with double strand-like properties. J Mol Biol (1969) 2.71
Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc Natl Acad Sci U S A (2000) 2.70
Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc Natl Acad Sci U S A (1996) 2.68
Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest (1996) 2.65
Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol (2000) 2.65
Deoxyribonucleic acid replication in vitro. J Mol Biol (1972) 2.64
Nucleotide sequence and corresponding amino acid sequence of the gene for the major antigen of foot and mouth disease virus. Nucleic Acids Res (1981) 2.61
Transmission of type B viral hepatitis to chimpanzees. J Infect Dis (1973) 2.51
Biochemical and immunological characterization of the duck hepatitis B virus envelope proteins. J Virol (1987) 2.50
Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol (1997) 2.50
HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med (1993) 2.49
Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol (2000) 2.49
Single RNA polymerase binding site isolated. Nat New Biol (1972) 2.47
Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol (1996) 2.47
A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science (1985) 2.47
The duck hepatitis B virus core protein contains a highly phosphorylated C terminus that is essential for replication but not for RNA packaging. J Virol (1989) 2.47
Mapping and characterization of promoters in bacteriophages fd, f1 and m13. J Mol Biol (1975) 2.46
Hepatitis B virus replication. Trends Microbiol (1993) 2.41
Isolation and characterization of thermosensitive Escherichia coli mutants defective in deoxyribonucleic acid replication. J Bacteriol (1973) 2.38
Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology (2001) 2.38
Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus. J Virol (1989) 2.27
Translational inactivation of RNA function: discrimination against a subset of genomic transcripts during HBV nucleocapsid assembly. Cell (1990) 2.26
Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice. J Virol (1992) 2.25
Infectious hepatitis B virus from cloned DNA of known nucleotide sequence. Proc Natl Acad Sci U S A (1985) 2.20
An RNA transcribed from DNA at the origin of phage fd single strand to replicative form conversion. Proc Natl Acad Sci U S A (1978) 2.19
Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med (1994) 2.18
Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science (1985) 2.18
The intergenic region and the origins for filamentous phage DNA replication. Cold Spring Harb Symp Quant Biol (1979) 2.15
Cloning of cDNA of major antigen of foot and mouth disease virus and expression in E. coli. Nature (1981) 2.14
Protein fusions with the kanamycin resistance gene from transposon Tn5. EMBO J (1984) 2.13
Immune pathogenesis of hepatocellular carcinoma. J Exp Med (1998) 2.11
Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest (1994) 2.10
Hepadnavirus P protein utilizes a tyrosine residue in the TP domain to prime reverse transcription. J Virol (1994) 2.10
Cleavage site of bacteriophage fd gene II-protein in the origin of viral strand replication. Nature (1979) 2.09
Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest (1991) 2.08
Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice. J Virol (1998) 2.06
To kill or to cure: options in host defense against viral infection. Curr Opin Immunol (1996) 2.06
Class I-restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo. J Immunol (1994) 2.05
Hepadnavirus infection requires interaction between the viral pre-S domain and a specific hepatocellular receptor. J Virol (1993) 2.05
Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest (1996) 2.04
A tandem repeat gene in a picornavirus. Nucleic Acids Res (1982) 2.03
Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest (1996) 1.96